Objective:To analyze the epidemiological characteristics of rabies in China during 2024 to understand the patterns of disease transmission and provide a scientific basis for optimizing prevention strategies and advancing the rabies elimination process.Methods:Data on the national rabies epidemic in 2024 and case-specific information from national surveillance sites were collected from China's National Notifiable Disease Reporting System（NNDRS）. Descriptive epidemiological methods were used to analyze the disease trends and epidemic characteristics.Results:In 2024，China reported 167 human rabies cases across 20 provincial-level administrative divisions（PLADs），resulting in 148 fatalities. This represents a 39.17% increase from 2023（120 cases）and the highest annual incidence recorded since 2019. The epidemic exhibited a distinct geographic clustering in central and southern China，with four provinces（Henan，Guangxi，Hunan，and Hubei）accounting for 62.87%（105/167）of nationally reported cases. October（20 cases）and November（20 cases）recorded the highest monthly incidence，while February had the lowest（2 cases）. Farmers constituted the primary affected demographic（80.84%），with a marked male predominance（male-to-female ratio：2.15∶1）-higher than the 2023 ratio（1.86∶1）. Cases spanned all age groups，predominantly affecting middle-aged and older adults. Analysis of 54 cases revealed dogs as the primary exposure source（93.88%），with domestic dogs constituting 75.00% of these.The laboratory diagnosis rate of rabies cases in 2024 was 43.71%（73/167）.Conclusion:After 16 consecutive years of decline，China's rabies epidemic rebounded in 2024，primarily driven by deficiencies in domestic dog management and weaknesses in post-exposure prophylaxis. Key recommendations include enhancing canine vaccination coverage in high-risk areas，implementing targeted health education for farmers and middle-aged and older adults，improving standardized post-exposure treatment protocols，and optimizing integrated surveillance-alert-response systems，ultimately advancing the achievement of rabies elimination goals.

Objective:To analyze the epidemiological characteristics of rabies in China during 2024 to understand the patterns of disease transmission and provide a scientific basis for optimizing prevention strategies and advancing the rabies elimination process.Methods:Data on the national rabies epidemic in 2024 and case-specific information from national surveillance sites were collected from China's National Notifiable Disease Reporting System（NNDRS）. Descriptive epidemiological methods were used to analyze the disease trends and epidemic characteristics.Results:In 2024，China reported 167 human rabies cases across 20 provincial-level administrative divisions（PLADs），resulting in 148 fatalities. This represents a 39.17% increase from 2023（120 cases）and the highest annual incidence recorded since 2019. The epidemic exhibited a distinct geographic clustering in central and southern China，with four provinces（Henan，Guangxi，Hunan，and Hubei）accounting for 62.87%（105/167）of nationally reported cases. October（20 cases）and November（20 cases）recorded the highest monthly incidence，while February had the lowest（2 cases）. Farmers constituted the primary affected demographic（80.84%），with a marked male predominance（male-to-female ratio：2.15∶1）-higher than the 2023 ratio（1.86∶1）. Cases spanned all age groups，predominantly affecting middle-aged and older adults. Analysis of 54 cases revealed dogs as the primary exposure source（93.88%），with domestic dogs constituting 75.00% of these.The laboratory diagnosis rate of rabies cases in 2024 was 43.71%（73/167）.Conclusion:After 16 consecutive years of decline，China's rabies epidemic rebounded in 2024，primarily driven by deficiencies in domestic dog management and weaknesses in post-exposure prophylaxis. Key recommendations include enhancing canine vaccination coverage in high-risk areas，implementing targeted health education for farmers and middle-aged and older adults，improving standardized post-exposure treatment protocols，and optimizing integrated surveillance-alert-response systems，ultimately advancing the achievement of rabies elimination goals.

Objective:This study was performed using preclinical transplanted animal experiments to analyce the effects and mechanisms of third-generation EGFR-TKIs combined with anti-angiogenic therapy, thereby providing theoretical basis for further clinical trials. Methods:Researchers constructed the transplant BALB/C nude mice models with H1975 lung adenocarcinoma cell line (EGFR T790M) and divided the mice into four groups and treated them with osimertinib (2.5 or 5 mg/kg/day, gavage) alone or plus bevacizumab (5 mg/kg/twice weekly, i.p.) when the tumors reached approximately 0.4-0.6 cm3 in volume. The tumor growth curve of tumor volume was drawn according to the time in every group. After 2 weeks of treatment, the mice were killed and the tumors were processed for immunohistochemical staining and Western blot analysis. Immunostaining was performed to detect:HIF-1α, VEGF, and microvessel density (MVD) by using SP method on paraffin sections. Western blot analysis was used to analyze the protein expression levels of EGFR, AKT, and ERK signal transduction pathways. Results:After 2 weeks of treatment in high-and low-dose osimertinib alone, tumor volume in the high-dose group was significantly less than in low-dose osimertinib-alone group (P<0.05). VEGF, HIF-1αexpression, and MVD were significantly low in the high-dose osimertinib-alone group (P<0.05). Increasing doses of osimertinib induced dose-dependent weakening of the p-EGFR, p-AKT, and p-ERK expression levels (P<0.05). In the low-dose osimertinib-plus-bevacizumab group and low-dose osimertinib-alone group, no significant difference in tumor volume and the above factors was observed. In the low-dose osimertinib-plus-bevacizumab group and high-dose osimertinib-alone group, tumor volumes did not exhibit significant difference (P=0.178). Moreover, VEGF, HIF-1αexpression, and MVD exhibited no significant difference. No significant difference in the p-EGFR, p-AKT, and p-ERK expression levels was found between high-dose osimertinib-alone group and low-dose osimertinib-plus-bevacizumab group (P>0.05). In the high-dose osimertinib-plus-bevacizumab group, tumor growth was not significantly greater than that in the high-dose osimertinib-alone group (P=0.642). No significant difference was observed in the above factors.In the high-and low-dose osimertinib-plus-bevacizumab groups, tumor volume and the above factors did not exhibit significant differences (P>0.05). Conclusion:Osimertinib has obvious antitumor effects in EGFR-mutant lung adenocarcinoma with T790M mutation cell xenografts. Bevacizumab has a synergetic inhibitory effect with osimertinib against EGFR-mutant lung adenocarcinoma with T790M mutation cell xenografts. Bevacizumab enhanced the antitumor effects of osimertinib by reducing VEGF expression and the microvascular density of the tumor, thereby improving the tumor microenvironment. Bevacizumab can enhance the effect of osimertinib by suppressing EGFR, ERK, and AKT phosphorylation, thereby synergistically inhibiting EGFR activation and downstream signaling.